2021
DOI: 10.1016/j.clml.2020.12.020
|View full text |Cite
|
Sign up to set email alerts
|

Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 7 publications
(1 citation statement)
references
References 30 publications
0
1
0
Order By: Relevance
“… 15 In addition, following each relapse, FL patients experience decrease in duration of each subsequent remission, with eventual exhaustion of therapeutic options, indicating an unmet therapeutic need. 16 Another therapeutic challenge is that CD20 is variably expressed on FL. 17 CD20 level is predictive for response to rituximab in a diverse group of B-cell lymphomas.…”
Section: Introductionmentioning
confidence: 99%
“… 15 In addition, following each relapse, FL patients experience decrease in duration of each subsequent remission, with eventual exhaustion of therapeutic options, indicating an unmet therapeutic need. 16 Another therapeutic challenge is that CD20 is variably expressed on FL. 17 CD20 level is predictive for response to rituximab in a diverse group of B-cell lymphomas.…”
Section: Introductionmentioning
confidence: 99%